Loading...

Gino In

Title(s)Assistant Professor of Clinical Medicine
Phone+1 323 226 7622
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Southern California, Los Angeles, CAFellowship2016Hematology/Oncology
    SUNY Downstate Medical Center, Brooklyn, NYResidency2011Internal Medicine
    SUNY Downstate Medical Center, Brooklyn, NYInternship2010
    Ross University, North Brunswick Township, NJMD2010Medicine
    Emory University, Atlanta, GAMPH2006Environmental/Occupational Health
    Emory University, Atlanta, GABS2002
    Collapse Awards and Honors
    University of Southern CaliforniaChief Medical Oncology Fellow

    Collapse Overview 
    Collapse Overview
    Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. PMID: 31516991.
      View in: PubMed
    2. Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, In GK, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. Skin cancer and dermatoses in a majority Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2019 Aug 07. PMID: 31400454.
      View in: PubMed
    3. Snow A, Ricker C, In GK. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6). PMID: 31227566.
      View in: PubMed
    4. Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693. PMID: 30979895.
      View in: PubMed
    5. Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, Wysong A. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267. PMID: 30672860.
      View in: PubMed
    6. Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. PMID: 30450405.
      View in: PubMed
    7. Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261. PMID: 29894433.
      View in: PubMed
    8. In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). PMID: 30283700.
      View in: PubMed
    9. In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3).
    10. Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017.
    11. In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. PMID: 28794805.
      View in: PubMed
    12. In GK, Nieva J.Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355.
    13. In G, Dorff T. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. PMID: 26216822.
      View in: PubMed